SCHEMBL919159

SCHEMBL919159

NC1CC2(CCC2)Oc2c(Cl)cccc21

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.38
TRPV1 Q8NER1 1/20 0.36
KDM1A O60341 2/20 0.35
HTR2C P28335 3/20 0.33
HTR2B P41595 3/20 0.33
HTR2A P28223 2/20 0.33
OPRD1 P41143 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31
DPP4 P27487 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
KCNH2 Q12809 1/20 0.30
GAA P10253 1/20 0.30
AGTR1 P30556 1/20 0.30
AADAT Q8N5Z0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3800669 1.00 TRPM8 (0.38) TRPM8TRPV1KDM1AHTR2CHTR2B
SCHEMBL3797219 1.00 TRPM8 (0.38) TRPM8TRPV1KDM1AHTR2CHTR2B
Hydrochloric Acid SCHEMBL13516693 0.98 TRPM8 (0.38) TRPM8TRPV1KDM1AHTR2CHTR2B
Hydrochloric Acid SCHEMBL616989 0.81 DRD1 (0.34) HTR2CHTR2BHTR2AOPRD1
SCHEMBL617759 0.79 HTR2A (0.32) KDM1AHTR2A
SCHEMBL617985 0.78 OPRD1 (0.47) TRPV1OPRD1KMT2AKCNH2
SCHEMBL15021498 0.78 OPRD1 (0.47) TRPV1OPRD1KMT2AKCNH2
SCHEMBL3798522 0.77 TRPM8 (0.30) TRPM8KDM1A
Hydrochloric Acid SCHEMBL619743 0.76 OPRD1 (0.46) TRPV1OPRD1KMT2AKCNH2
SCHEMBL3713990 0.76 TRPM8 (0.53) TRPM8TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
EP-1931681-B1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS SA (CH) 2012-11-14 EP disclosed
US-20110021549-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS S.A. (CH) 2011-01-27 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 TRPM8 9/4885TRPV1 3/4885KDM1A 3314/4885
US-20110021549-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS TRPV1, GPR17, TRPV6 TRPM8 24/4885TRPV1 1/4885KDM1A 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.